Dashboard
Manage Tickers

HOTH Hoth Therapeutics, Inc.

Nasdaq hoththerapeutics.com


$ 1.37 $ 0.01 (0.74 %)    

Friday, 24-Oct-2025 19:04:44 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 1.37
$ 1.39
$ 1.28 x 481
$ 1.47 x 1,700
$ 1.35 - $ 1.41
$ 0.66 - $ 3.80
328,375
na
18.06M
$ 0.55
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-29-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 04-01-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hoth-therapeutics-announces-its-precision-antisense-oligonucleotide-ht-kit-receives-fda-orphan-drug-designation-and-new-preclinical-data-show-ht-kit-achieves-over-80-suppression-of-kit-expression-and-significant-tumor-volume-reduction-by-day-8-in-systemic-mastocytosis-and-gist-models
Hoth Therapeutics Announces Its Precision ...
10/21/2025 12:26:16

Hoth Therapeutics, Inc. (NASDAQ: HOTH) today highlighted FDA Orphan Drug Designation for HT-KIT and new preclinical data demons...

Core News & Articles
Hoth Therapeutics Expands Its AI Initiativ...
10/08/2025 14:24:38

Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its G...

hoth-therapeutics-to-present-ht-001-and-ht-kit-oncology-programs-at-bio-europe-2025
Hoth Therapeutics To Present HT-001 And HT...
10/07/2025 12:00:06

Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-...

hoth-therapeutics-expands-intellectual-property-portfolio-for-ht-001-with-new-us-provisional-patent-filings-covering-novel-dermatological-indications
Hoth Therapeutics Expands Intellectual Pro...
09/24/2025 12:16:43

MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, ...

hoth-therapeutics-provides-shareholder-update-highlights-clinical-progress-and-crypto-treasury-reserve-expansion
Hoth Therapeutics Provides Shareholder Upd...
09/16/2025 12:15:16

hoth-therapeutics-approves-expansion-of-treasury-reserve-strategy-to-include-ethereum-and-solana-may-purchase-up-to-1m-in-bitcoin-ethereum-andor-solana-as-a-treasury-reserve-asset
Hoth Therapeutics Approves Expansion Of Tr...
09/12/2025 12:28:24

-SEC Filing

hoth-therapeutics-submits-cta-to-ema-to-expand-ongoing-phase-ii-trial-of-ht-001-topical-therapeutic-for-skin-toxicities-associated-with-egfri
Hoth Therapeutics Submits CTA To EMA To Ex...
09/10/2025 12:32:33

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clini...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/02/2025 21:06:39

top-5-biotech-stocks-with-strong-momentum
Top 5 Biotech Stocks With Strong Momentum
08/28/2025 11:19:00

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

d-boral-capital-maintains-buy-on-hoth-therapeutics-maintains-5-price-target
D. Boral Capital Maintains Buy on Hoth The...
08/18/2025 11:25:50

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

d-boral-capital-maintains-buy-on-hoth-therapeutics-maintains-5-price-target
D. Boral Capital Maintains Buy on Hoth The...
07/30/2025 11:34:48

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

hoth-therapeutics-engages-with-icon-clinical-research-to-expand-phase-ii-clinical-trial-for-cancer-patients-suffering-from-skin-toxicities-associated-with-egfri
Hoth Therapeutics Engages With ICON Clinic...
07/29/2025 11:59:56

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countri...

d-boral-capital-maintains-buy-on-hoth-therapeutics-maintains-5-price-target
D. Boral Capital Maintains Buy on Hoth The...
07/23/2025 11:10:07

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

hoth-therapeutics-announces-crada-with-us-department-of-veterans-affairs-and-faver-to-evaluate-gdnf-as-metabolic-therapy-targeting-obesity-and-hepatic-steatosis
Hoth Therapeutics Announces CRADA With U.S...
07/22/2025 12:20:39

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and ...

d-boral-capital-maintains-buy-on-hoth-therapeutics-maintains-5-price-target
D. Boral Capital Maintains Buy on Hoth The...
06/26/2025 11:16:13

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.

Core News & Articles
Hoth Therapeutics And Silo Pharma Form Str...
06/25/2025 12:29:49

*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Marke...

hoth-therapeutics-ht-001-achieves-100-response-in-phase-2a-trial-for-egfr-inhibitor-related-skin-toxicities
Hoth Therapeutics' HT-001 Achieves 100% Re...
06/24/2025 14:37:43

Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR In...

hoth-therapeutics-regains-full-compliance-with-nasdaqs-minimum-bid-price-requirement
Hoth Therapeutics Regains Full Compliance ...
06/18/2025 17:36:23

hoth-therapeutics-releases-preclinical-safety-data-for-cancer-fighting-ht-kit-including-100-clean-safety-profile-and-no-adverse-effects-on-kidney-spleen-or-thymus
Hoth Therapeutics Releases Preclinical Saf...
06/18/2025 12:24:32

HOTH ALERT: Hoth Therapeutics Reports Positive Preclinical Safety Data for HT-KIT — Dose-Dependent Activity, No Toxicity, IND o...

hoth-therapeutics-secures-japan-patent-for-ht-kit-platform-granted-exclusive-protection-until-aug-27-2039
Hoth Therapeutics Secures Japan Patent For...
06/12/2025 13:18:29

Protection through 2039, ensuring long-term commercial exclusivity.NEW YORK, June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, I...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION